Hib-DTaP-Hepatitis-B-Poliovirus-vaccine - Merck

Drug Profile

Hib-DTaP-Hepatitis-B-Poliovirus-vaccine - Merck

Alternative Names: DTaP5-HepB-Polio-Hib - Merck; DTP-HepB-Polio-Hib vaccine - Merck; Pediatric hexavalent vaccine; Pediatric hexavalent vaccine PR5i; PR5I; V419; Vaxelis

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Merck & Co; sanofi pasteur
  • Developer Merck & Co; Sanofi Pasteur
  • Class Haemophilus vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 02 Jan 2017 Sanofi Pasteur MSD ended their joint venture and will separately pursue their vaccine strategies in Europe
  • 21 Mar 2016 Phase-III clinical trials in Tetanus, Pertussis, Poliomyelitis, Hepatitis B, Haemophilus infections and Diphtheria (In children, Prevention) in Finland (IM) (EudraCT2016-000274-37)
  • 26 Feb 2016 Merck has patents pending for Hib-DTaP-Hepatitis-B-Poliovirus-vaccine in USA (Merck & Co 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top